510 related articles for article (PubMed ID: 18952572)
1. Arachidonic acid cytochrome P450 epoxygenase pathway.
Spector AA
J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S52-6. PubMed ID: 18952572
[TBL] [Abstract][Full Text] [Related]
2. Action of epoxyeicosatrienoic acids on cellular function.
Spector AA; Norris AW
Am J Physiol Cell Physiol; 2007 Mar; 292(3):C996-1012. PubMed ID: 16987999
[TBL] [Abstract][Full Text] [Related]
3. Epoxyeicosatrienoic acid pathway in human health and diseases.
Bellien J; Joannides R
J Cardiovasc Pharmacol; 2013 Mar; 61(3):188-96. PubMed ID: 23011468
[TBL] [Abstract][Full Text] [Related]
4. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.
Spector AA; Fang X; Snyder GD; Weintraub NL
Prog Lipid Res; 2004 Jan; 43(1):55-90. PubMed ID: 14636671
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation.
Deng Y; Theken KN; Lee CR
J Mol Cell Cardiol; 2010 Feb; 48(2):331-41. PubMed ID: 19891972
[TBL] [Abstract][Full Text] [Related]
6. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition.
Larsen BT; Miura H; Hatoum OA; Campbell WB; Hammock BD; Zeldin DC; Falck JR; Gutterman DD
Am J Physiol Heart Circ Physiol; 2006 Feb; 290(2):H491-9. PubMed ID: 16258029
[TBL] [Abstract][Full Text] [Related]
7. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
[TBL] [Abstract][Full Text] [Related]
8. Influence of inflammation on cardiovascular protective effects of cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids.
Shahabi P; Siest G; Visvikis-siest S
Drug Metab Rev; 2014 Feb; 46(1):33-56. PubMed ID: 24040964
[TBL] [Abstract][Full Text] [Related]
9. CYP450 Epoxygenase Metabolites, Epoxyeicosatrienoic Acids, as Novel Anti-Inflammatory Mediators.
Shi Z; He Z; Wang DW
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744996
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 eicosanoids are activators of peroxisome proliferator-activated receptor alpha.
Ng VY; Huang Y; Reddy LM; Falck JR; Lin ET; Kroetz DL
Drug Metab Dispos; 2007 Jul; 35(7):1126-34. PubMed ID: 17431031
[TBL] [Abstract][Full Text] [Related]
11. Epoxide hydrolase 1 (EPHX1) hydrolyzes epoxyeicosanoids and impairs cardiac recovery after ischemia.
Edin ML; Hamedani BG; Gruzdev A; Graves JP; Lih FB; Arbes SJ; Singh R; Orjuela Leon AC; Bradbury JA; DeGraff LM; Hoopes SL; Arand M; Zeldin DC
J Biol Chem; 2018 Mar; 293(9):3281-3292. PubMed ID: 29298899
[TBL] [Abstract][Full Text] [Related]
12. The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases.
Xu X; Zhang XA; Wang DW
Adv Drug Deliv Rev; 2011 Jul; 63(8):597-609. PubMed ID: 21477627
[TBL] [Abstract][Full Text] [Related]
13. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
Nayeem MA; Geldenhuys WJ; Hanif A
Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
[TBL] [Abstract][Full Text] [Related]
14. EET signaling in cancer.
Panigrahy D; Greene ER; Pozzi A; Wang DW; Zeldin DC
Cancer Metastasis Rev; 2011 Dec; 30(3-4):525-40. PubMed ID: 22009066
[TBL] [Abstract][Full Text] [Related]
15. DiscrEET regulators of homeostasis: epoxyeicosatrienoic acids, cytochrome P450 epoxygenases and vascular inflammation.
Fleming I
Trends Pharmacol Sci; 2007 Sep; 28(9):448-52. PubMed ID: 17764757
[TBL] [Abstract][Full Text] [Related]
16. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.
Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A
Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease.
Theken KN; Schuck RN; Edin ML; Tran B; Ellis K; Bass A; Lih FB; Tomer KB; Poloyac SM; Wu MC; Hinderliter AL; Zeldin DC; Stouffer GA; Lee CR
Atherosclerosis; 2012 Jun; 222(2):530-6. PubMed ID: 22503544
[TBL] [Abstract][Full Text] [Related]
18. The factor in EDHF: Cytochrome P450 derived lipid mediators and vascular signaling.
Fleming I
Vascul Pharmacol; 2016 Nov; 86():31-40. PubMed ID: 26975734
[TBL] [Abstract][Full Text] [Related]
19. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
Elmarakby AA
Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
[TBL] [Abstract][Full Text] [Related]
20. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.
Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL
Circ Res; 2000 Nov; 87(11):992-8. PubMed ID: 11090543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]